Edwards Lifesciences Corporation

NYSE:EW

Medical - Devices

Healthcare
$105.23 +0.57%

+$0.49 today

Market cap
$60.51B
Beta
0.87
P/E (TTM)
46.2
EPS (TTM)
$1.89
52W Low $72.30High $89.60

Volume 3.92M

Average 5.02M

EW Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Edwards Lifesciences CorporationNYSE: EW

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows in line with its trailing trend

Q2 FY2026 revenue of $1.74B rose 13.6% year over year, behind the +14.6% change in trailing-twelve-month revenue. Sequentially, it rose 5.6% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 21 analysts of $6.81B (+12.3%) for the fiscal year ending Dec 2026, a pace similar to FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.74B+5.6% QoQ
Last fiscal yearDec 2025
$6.07B+11.5% YoY
LTMJun 2026
$6.51B+14.6% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.6%+8.2%-5.4 pp
1 year+11.5%+12.3%+0.7 pp
3-year CAGR+4.1%+10.8%+6.7 pp
5-year CAGR+10.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
6.07B USD
Year-over-year change
+11.5%
4-year CAGR
+3.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How EW compares with its peers on the latest reported figures

  • EW's LTM Jun 2026 revenue of $6.51B is the 2nd highest of the 6 companies compared; the peer median is $1.5B.
  • Its year-over-year change of +14.6% is the 4th highest of 6, against a peer median of +17.6%.
  • Over three fiscal years its annual growth of +4.1% compares with a peer median of +12.0%.
EW Competitors Peer median
Revenue for EW and competitors
Company Period LTM YoY 3-year CAGR
ISRGIntuitive Surgical, Inc.LTM Sep 2026$11.58B +20.5%+17.4%
EWEdwards Lifesciences CorporationLTM Jun 2026$6.51B +14.6%+4.1%
LIVNLivaNova PLCLTM Sep 2026$1.51B +11.7%+10.8%
PENPenumbra, Inc.LTM Jun 2026$1.5B +17.6%+18.3%
AORTArtivion, Inc.LTM Mar 2026$458.69M +17.6%+12.0%
AVRAnteris Technologies Global Corp.LTM Mar 2026$1.85M -25.7%-15.8%
Peer median (excluding EW) $1.5B+17.6%+12.0%

Competitors are the stored peer set for EW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.23B5.38B5.01B5.44B6.07B
Cost of Revenue1.23B1.17B1.04B1.12B1.33B
Gross Profit4.01B4.22B3.97B4.32B4.74B
Gross Margin76.6%78.3%79.3%79.5%78.1%
Research & Development903.1M945.2M962.9M1.05B1.08B
Selling, General & Admin1.49B1.57B1.58B1.79B2.09B
Operating Expenses2.4B2.51B2.55B2.94B3.1B
Depreciation & Amortization134.8M139.6M144.9M155.2M156.6M
EBITDA1.86B1.93B1.53B1.72B1.43B
EBITDA Margin35.6%35.9%30.6%31.7%23.6%
Operating Income1.61B1.7B1.43B1.38B1.64B
Operating Margin30.8%31.6%28.5%25.3%27.0%
Interest Income17.4M35.5M67.2M120.3M148.4M
Interest Expense24.8M26.2M17.6M19.8M0
Other Income / Expenses91.6M65M(54.9M)169.4M(363.3M)
Income Before Tax1.7B1.77B1.37B1.55B1.27B
Pre-Tax Margin32.5%32.8%27.4%28.5%21.0%
Income Tax Expense198.9M245.5M152.4M152.1M216.9M
Net Income1.5B1.52B1.4B4.17B1.07B
Net Margin28.7%28.3%28.0%76.7%17.7%
EPS (Basic)2.412.462.316.981.84
EPS (Diluted)2.382.442.306.971.83
Weighted Avg Shares623.3M619M606.7M597.7M584.8M
Weighted Avg Shares (Diluted)631.2M624.2M609.4M599.3M585.8M

Edwards Lifesciences Corporation

NYSE:EW

Intrinsic Alpha fair value

Locked

Current Price

$105.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.